HIV moments and pre-exposure prophylaxis--Authors' reply.

David T Dunn, Mitzy Gafos, Ellen White, Sheena McCormack

Erratum issuedAbstract readLetterComment

In one paragraph

Article in Lancet (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Incentivizing adherence to pre-exposure prophylaxis for HIV prevention: a randomized pilot trial among male sex workers in Mexico.The European journal of health economics : HEPAC : health economics in prevention and care · 2025
Trial
Predictive factors for HIV infection among men who have sex with men and who are seeking PrEP: a secondary analysis of the PROUD trial.Sexually transmitted infections · 2019
Trial
Knowledge domain and emerging trends in HIV pre-exposure prophylaxis: A visualization analysisFrontiers in microbiology · 2023
Article

4 · The record

Corrections and comments

Comment on
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.2016
Comment on
HIV moments and pre-exposure prophylaxis.2016
Erratum issued
Department of Error.2016

5 · Who and what money

Authors and funding

4 authors.

David T DunnMRC Clinical Trials Unit, University College London, London WC2B 6NH, UK. Electronic address: d.dunn@ucl.ac.uk.

Mitzy GafosMRC Clinical Trials Unit, University College London, London WC2B 6NH, UK.

Ellen WhiteMRC Clinical Trials Unit, University College London, London WC2B 6NH, UK.

Sheena McCormackMRC Clinical Trials Unit, University College London, London WC2B 6NH, UK.

Funding

Medical Research Council MC_UU_12023/1Medical Research Council MC_UU_12023/23

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Unsafe SexAnti-HIV AgentsEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationHIV InfectionsHumansMalePre-Exposure ProphylaxisAnti-HIV AgentsEmtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

Identifiers

PMID27115971

DOI10.1016/S0140-6736(16)00695-4

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.